Recurrent Respiratory Papillomatosis (RRP) is a rare benign airway neoplasm caused by infection with human papillomavirus (HPV). It presents with wart-like growths or papillomatous lesions in the vocal cords and airway. RRP remains challenging to treat due to its high recurrence rate and the significant reduction in quality of life it causes.
In addition to surgical debridement, preliminary clinical trials and retrospective studies suggest that the HPV vaccine may offer therapeutic benefits, complementing its role in preventing HPV-related diseases. Bevacizumab (Avastin), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has also shown promise as a systemic treatment for RRP.
Current knowledge of the disease is still limited, and more robust controlled trials are needed to explore risk factors, medical therapies, and surgical options. Although rare, the lesions can undergo malignant transformation, with transformation rates ranging from 2% to 4%.
Vocal cords
Mid trachea
Snare resection
Snare resection
View from the distal trachea
L mainstem bronchus obstruction
Cryoablation
End result after APC
P16
Laryngoscope Investigative Otolaryngology.2021;6:340-345
Laryngoscope Investigative Otolaryngology.2021;6:226–233